

Current as of August 29, 2025

Poster Session A (To be presented on September 29 from 4:30-7 p.m.)

A002 **Targeting nuclear IL-17RA transcriptional regulation with a novel aptamer to treat hypoxia-induced pancreatic ductal adenocarcinoma**. Zheng Chen. Shum Yiu Foon Shum Bik Chuen Memorial Centre for Cancer and Inflammation Research, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China., Hong Kong, Taiwan (Greater China).

A003 **A Splicing Switch in ERK1 Controlled by SMNDC1 Drives MAPK Pathway Reactivation and Resistance to KRAS inhibitors in PDAC**. Md Afjalus Siraj. Yale University, New Haven, CT, United States.

A004 **Altered RNA splicing drives pancreatic cancer by mimicking chromosome deletions.**. Natasha Pinto Medici. Yale University, New Haven, NH, United States.

A005 **An Iron-regulated Signalling Pathway Controls Adipose Browning and Cancer Cachexia**. JungSeung Nam. Columbia University Medical Center, New York, NY, United States.

A006 **Assessing metabolic requirements for RAS inhibitor resistance in pancreatic cancer**. Sarah Ackermann. University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.

A007 **ATF4 is required for KRas-driven pancreatic tumorigenesis to suppress early-stage p53 induction.**. Leah Ziolkowski. University of Chicago, Chicago, IL, United States.

A008 **Biomarkers of cachexia due to pancreatic ductal adenocarcinoma: Results from two Danish studies**. Sidsel Lindgaard. Copenhagen University Hospital – Herlev and Gentofte, Herlev, Denmark; University of Copenhagen, Copenhagen, Denmark.

A009 **Characterizing the pre-metastatic liver in PDAC patients using scRNA-seq of FFPE tissue**. Ryan Humphrey. Duke University, Durham, NC, United States.

A010 **Chemotherapy-associated liver damage accelerates pancreatic cancer liver metastasis**. Nikki Lytle. Medical College of Wisconsin, Milwaukee, WI, United States.

A012 **Context-dependent role of TGM2 in Pancreatic Ductal Adenocarcinoma**. Polina Wright. Virginia Commonwealth University, Richmond, VA, United States.

A013 **CRISPR-engineered human organoid-based pancreatic cancer model recapitulates early tumor features through TP53 inactivation**. Eden Demere Amare. Hanyang University, Seoul, Korea, Republic of.

A014 **Dec2 drives tumor progression by facilitating immune evasion in pancreatic cancer**. Lan Wang. University of Rochester, Rochester, NY, United States.

A015 **Defining the spatial distribution of n-glycans and ECM peptides in primary pancreatic ductal adenocarcinoma, metastases and premalignant disease**. Caroline Kittrell. Medical University of South Carolina, Charleston, SC, United States.

A016 **Defining UHRF1 as a crucial factor in pancreatic cancer progression and treatment**. Austin Silva. University of California Irvine, Irvine, CA, United States.

A017 **Dual Targeting of KRAS and Nutrient Scavenging via SDC1 Inhibition Offers a Promising Therapeutic Strategy in Pancreatic Cancer**. Shuaitong Chen. The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

A018 **Epigenetic silencing of TMEM240drives metastatic progression in advanced pancreatic cancer: A promising cfDNA biomarker for monitoring intra-abdominal metastatic spread and clinical progression**. Ruo-Kai Lin. Taipei Medical University, Taipei, Taiwan (Greater China).

A019 **Epigenetic Tumor Suppressor KMT2D Shapes the Immune Landscape in Pancreatic Cancer**. Heizel Acosta. University of Michigan, Ann Arbor, MI, United States.

A020 **Evaluating oncogenic roles of ABI1 isoforms and metastatic potential through alternative splicing deregulation in pancreatic cancer**. Karen Mann. Moffitt Cancer Center, Tampa, FL, United States.

A021 **Examining the unconventional role of Ang–Tie2 signaling in pancreatic CAF/ECM unit function**. Jaye Gardiner. Tufts University, Medford, MA, United States.

A022 **Extracellular matrix sensing shapes the heterogeneity of autophagic flux and biological responses in pancreatic cancer**. Mohamad Assi. Department of Radiation Oncology, New York University Langone Health, New York, NY, USA, New York, NY, United States.

A023 **Fibroblast STAT3 activation drives organ-specific premetastatic niche formation**. Emily Lasse Opsahl. University of Michigan, Ann Arbor, MI, United States.

A024 **Fibroblast-specific inhibition of p38αMAPK reprograms the tumor stroma to overcome therapeutic resistance in pancreatic cancer**. Camille Acevedo. University of Miami Miller School of Medicine, Miami, FL, United States.

A025 **Genomics-informed agent-based models drive new understanding of the role of neoplastic phenotype transitions in human PDAC invasion**. Jeanette Johnson. University of Maryland School of Medicine, Baltimore, MD, United States.

A026 **Hereditary chronic pancreatitis induced plasticity cooperates with mutant Kras in early pancreatic carcinogenesis**. Tanvi Inamdar. Department of Internal Medicine I, University Medicine Halle, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.

A027 **HuR drives immune evasion, metastases and KRAS addiction in pancreatic ductal adenocarcinoma: implications for IO-based and KRAS inhibitor therapies.**. Miffy Guo. Oregon Health & Science University, Portland, OR, United States.

A028 **Identification of cancer-specific regulators of ΔNp63 through CRISPR-Cas12a screening in pancreatic and head and neck cancers**. Shengmiao Chen. Dana-Farber Cancer Institute, BOSTON, MA, United States.

A029 **Identification of THOC3 as a key regulator of subtype specification in basal-squamous pancreas cancer**. Hannah Pettit. Columbia University, New York, NY, United States.

A030 **Inactivation of CDKN2AARF promotes p53-independent remodeling of the PDAC tumor microenvironment**. Sofia Ferreira. Stanford University School of Medicine, Stanford, CA, United States.

A031 **Interrogating microenvironmental changes that impact early pancreatic cancer development**. Ellen Langer. Oregon Health & Science University, Portland, OR, United States.

A032 **Interstitial insulin enrichment drives pancreatic cancer growth by enhancing cancer cellmetabolic plasticity**. Jeffrey Lin. Life Sciences Institute, University of British Columbia, Vancouver, BC, Canada.

A033 **Investigating the role of LKB1/STK11 in pancreatic cancer**. Shira Yomtoubian. Salk Institute, La Jolla, CA, United States.

A034 **Ketogenic diet prevents obesity-associated pancreatic cancer independent of weight loss and induces pancreatic metabolic reprogramming**. Ericka Velez-Bonet. The Ohio State University, Columbus, OH, United States.

A035 **KMT2D Loss Induces Enrichment of Plod2+ Fibroblasts in Pancreatic Cancer**. Kaiyue Ding. Department of Pathology & Clinical Labs, Rogel Cancer Center and Center for RNA Biomedicine, University of Michigan, Ann Arbor, MI, United States.

A036 **Kras-driven proteostatic dysfunction primes pancreatic epithelial cells for tumorigenesis**. Carla Salomo Coll. University of Edinburgh, Edinburgh, United Kingdom.

A037 **Linking reactive oxygen species andneutrophil extracellular traps formation topancreatic ductal adenocarcinoma progression.**. Angisha Basnet. West Virginia University, Morgantown, WV, United States.

A039 **Multi-omic analyses of pancreatic ductal adenocarcinoma patients of African ancestry**. Emmanuel Nweke. University of Witwatersrand, Johannesburg, South Africa.

A040 **Multi-omic Analyses Of The Tumour Microenvironment Of South African Pancreatic Ductal Adenocarcinoma Patients.**. Sinegugu Dubazana. University of the Witwatersrand, Pretoria, South Africa.

A041 **Neil2 is a potential theratputic targert in pancreatic cancer**. Fan Meng. City of Hope National Medical Center, Duarte, CA, United States.

A042 **Opioids drive extracellular matrix remodeling in the pancreatic tumor microenvironment**. Kathryn Maraszek. Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.

A043 **p53 licenses transcriptional regulation by TEAD to dictate cell fate in pancreatic ductal adenocarcinoma**. Cole Martin. University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.

A044 **Pancreatic cancer cell-derived EVs facilitate monocyte recruitment to the tumor site**. Amrita Cheema. Georgetown University, Washington, DC, United States.

A045 **Pancreatic cancer-associated systemic nutrient starvation elevates autophagic proteolysis in the muscle**. *Yetis Gultekin. Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, MA, United States.

A046 **Quantitative, multiplex assessment of the pancreatic microenvironment in individuals at high-risk of pancreatic cancer reveals differences in tumorigenesis**. Lucie Dequiedt. Johns Hopkins University, Baltimore, MD, United States.

A047 **Ras-dependent activation of BMAL2 regulates hypoxic metabolism in pancreatic cancer**. Alvaro Curiel Garcia. Columbia University, New York, NY, United States.

A048 **Robust Pancreatic Cancer Liver Metastatic Model System Reveals Cancer Cell Dependent Organotropism and Site-specific Tumor Microenvironment Regulation**. Julienne Carstens. The University of Alabama at Birmingham, Birmingham, AL, United States.

A049 **Sialic acid depletion leads to profound remodelling of glycocalyx architecture and mechanics in pancreatic cancer cells**. Andrew Massey. National Institutes of Health, Bethesda, MD, United States.

A050 **Single nuclei "AdipoMap" from esectable PDAC demonstrates differences in the visceral adipose tissue microenvironment related to obesity status.**. Zachary Hurst. The Ohio State University, Columbus, OH, United States.

A051 **Spatial features of the tumor microenvironment predict recurrence risk in resected pancreatic ductal adenocarcinoma after total neoadjuvant therapy**. Miranda Lin. Mayo Clinic, Rochester, MN, United States.

A052 **Spatially Resolved Insights into epithelial-stromal co-evolution in pancreatic ductal adenocarcinoma**. Ahmed Elhossiny. University of Michigan, Ann Arbor, MI, United States.

A053 **Steroid receptors modulate oncogenic signaling and drive cell migration in pancreatic ductal adenocarcinoma**. Oliver Stockert. University of Minnesota, Minneapolis, MN, United States.

A054 **Stromal dynamics in PDAC: The role of NetrinG proteins in regulating fibroblast function**. Aleksandr Dolskii. Fox Chase Cancer Center, Philadelphia, PA, United States.

A055 **Targeting myeloid metabolism to remodel the pancreatic tumor immune microenvironment.**. Mariam Mohagheghi. University of California Irvine, Irvine, CA, United States.

A056 **Targeting the Protein Regulator of Cytokinesis 1 (PRC1) Pathway in Pancreatic Cancer**. Amnon Peled. Goldyne Savad Institute of Gene Therapy, Hadassah Hebrew University Hospital, Jerusalem, Israel.

A057 **The establishment of Th1 versus Th2 driven models of experimental pancreatitis**. Corey Perkins. Dana-Farber Cancer Institute, Boston, MA, United States.

A058 **TheInfluenceofWDR-62inc-Jun-N-terminalKinaseon the Spatiotemporal Regulation of JNKActivation in Pancreatic DuctalAdenocarcinoma**. SDANISH KADIR. University of Texas Rio Grande Valley, Edinburg, TX, United States.

A059 **The role of Lamin A in pancreatic cancer nuclear envelope stability**. Kayla LaRue-Nolan. Mayo Clinic, Rochester, MN, United States.

A060 **Tightly regulated alternative RNA splicing of MAPK3 (ERK1) as a Kras-independent mechanism of oncogenesis in PDAC**. Deanne Yugawa. Yale University, New Haven, CT, United States.

A061 **TIGIT-mediated immune suppression in KMT2D-mutant pancreatic cancer**. Shungang Zhang. University of Michigan, Ann Arbor, MI, United States.

A062 **Transcriptional and Chromatin Remodeling Programs Underlie Resistance to Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer**. Meet Patel. The University of Alabama at Birmingham, Birmingham, AL, United States.

A063 **UNC5B orchestrates the metastatic traits of pancreatic ductal adenocarcinoma through EMT, invasion, and survival signaling**. Muhammad Sadeqi Nezhad. Wilmot Cancer Center, Rochester, NY, United States.

A064 **Uncoupling CX3CL1-CX3CR1 Axis in IPMN Development Through Transgenic Mouse Models**. Li Ding. Mayo Clinic, Rochester, MN, United States.

A065 **Upregulated expression of bulky glycoproteins modulates integrin-based adhesions in pancreatic cancer cells**. Elijah Marquez. National Institutes of Health, Bethesda, MD, United States.

A066 **Wilm's Tumor 1-Expressing Stromal Cells Promote Pancreatic Cancer Growth**. Allison Bischoff. University of Michigan, Ann Arbor, MI, United States.

A067 **βIII-tubulin is a dual cell therapeutic target in pancreatic cancer and regulates sensitivity to TRAIL through a DR5-dependent mechanism**. Grace Schulstad. Pancreatic Cancer Translational Research Group, School of Biomedical Sciences, Lowy Cancer Research Centre, UNSW Sydney, Sydney, NSW, Australia.

A068 **A phase 2 study to investigate the efficacy and safety of acoustic cluster therapy with modified FOLFIRINOX in patients with locally advanced pancreatic cancer**. Erin Pierce. HonorHealth Research Institute, Scottsdale, AZ, United States.

A069 **A phase I trial of emavusertib (CA-4948) in combination with gemcitabine and nab-paclitaxel in metastatic or unresectable pancreatic ductal adenocarcinoma (PDAC).**. Patrick Grierson. Washington University in St Louis, St Louis, MO, United States.

A070 **CENDIFOX: Phase I/II Trial of CEND-1 (LSTA1, certepetide) with Neoadjuvant mFOLFIRINOX in Resectable and Borderline Resectable PDAC**. Anup Kasi. University of Kansas Cancer Center, Kansas City, KS, United States.

A071 **Immune biomarkers of response in a phase 1 trial of combined MEK/STAT3/PD-1 inhibition in metastatic pancreatic ductal adenocarcinoma (PDAC)**. Nipun Merchant. Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine, Miami, FL, United States.

A072 **Monthly Alternating NALIRIFOX and GnP for Metastatic Pancreatic Ductal Adenocarcinoma (AltCAP)**. Daniel King. Northwell, New Hyde Park, NY, United States.

A074 **A novel nano-formulated taxoid (RP-001) enhances T-cell infiltration and prolongs survival in preclinical models of pancreatic ductal adenocarcinoma**. Laura Musumeci. University of California, Davis, Davis, CA, United States.

A075 **A Phase I Study of Autologous CAR-T Cells Targeting the B7-H3 Antigen and Containing the Inducible Caspase 9 Safety Switch in Subjects with Refractory Pancreatic Ductal Adenocarcinoma (PDAC)**. Ashwin Somasundaram. UNC, Chapel Hill, NC, United States.

A076 **Bypassing tumor microenvironment immune exclusion to elicit neoantigen-specific anti-tumor immunityin pancreatic cancer**. Jeremy Jacox. Yale University, New Haven, CT, United States.

A077 **Cancer-associated fibroblast (CAF) crosstalk with tumor cells bypasses cellular senescence and dampens responses to RAS pathway targeted therapy in PDAC**. Boyang Ma. UMass Chan Medical School, Worcester, MA, United States.

A078 **Choline metabolism promotes the immunosuppressive function of pancreatic tumor macrophages**. Vineeth Vengayil. University of Pennsylvania, PHILADELPHIA, PA, United States.

A079 **Conditional silencing of neutrophil-restricted Nlrp3 reveals an unrecognized role of MDSC-inflammasomes in driving stromal inflammation and chemoresistance in PDAC**. Karthik Rajkumar. University of Miami, Miami, FL, United States.

A080 **Deciphering the hierarchy of Notch signaling in the pancreatic tumor microenvironment**. Filip Bednar. University of Michigan, Ann Arbor, MI, United States.

A081 **Dissecting the Tumor–Immune Landscape of PDAC Liver Metastases to Identify Candidate Drivers of Immune Evasion and Metastatic Outgrowth**. Ayushi Mandloi. University of Alabama at Birmingham, Birmingham, AL, United States.

A082 **Distinct subsets of cytotoxic CD8 T cells delineate the rare pancreatic tumors that respond to PD-1 blockade**. Lestat Ali. Dana-Farber Cancer Institute, Boston, MA, United States.

A083 **Divergent Roles of TAM Receptors in Tumor and Stromal Compartments of Pancreatic Cancer**. Nancy Kren. University of North Carolina, Chapel Hill, NC, United States.

A084 **Dynamics of tumor immune environment across organs in early and late-stage metastatic pancreatic cancer**. Yu-Lan Kao. Washington University in St. Louis, St. Louis, MO, United States.

A085 **Elucidating the Crosstalk between Cancer Associated Fibroblasts and the T Regulatory/T Helper 2 Axis in Pancreas Cancer**. Padma Kadiyala. Michigan Medicine, Ann Arbor, MI, United States.

A086 **FAK inhibition improves CD40 agonist immunotherapy response and reduces MAPK signaling in pancreatic ductal adenocarcinoma**. Anna Thickens. University of Pennsylvania, Philadelphia, PA, United States.

A087 **FOLFIRONOX and Gemcitabine treatment alters formation and activity of tertiary lymphoid structures in pancreatic ductal adenocarcinoma patients**. Adam Tcharni. University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.

A088 **Genomic Scar to Immune Signals: Translational Insights from the POLAR Trial Reveal POLQ-Driven Immunogenicity in HRD Pancreatic Cancer**. Wungki Park. Memorial Sloan Kettering Cancer Center, New York, NY, United States.

A089 **Improving Therapeutic Window of Claudin 18.2-Targeted CAR-T cells in Pancreatic Cancer**. Elizabeth Carstens. Dana Farber Cancer Instititute, Boston, MA, United States.

A090 **Investigating the role of androgen signaling in the PDAC tumor microenvironment**. Quinn Hopen. West Virginia University, Morgantown, WV, United States.

A091 **KRAS Mutation-Specific Immune Microenvironments in Pancreatic Cancer**. Despina Siolas. Weill Cornell Medicine, New York, NY, United States.

A092 **Mesenchymal Stem Cells Shaping the TumorMicroenvironment in Metastatic PDAC: a Step Towards Clinical Translation**. Benedetta Ferrara. San Raffaele Scientific Institute, Milan, MI, Italy.

A093 **Multiplexed cytokine and antigen mRNA administration generates durable anti-tumor immunity against pancreatic cancer**. Chaitanya Naimesh Parikh. University of Massachusetts Chan Medical School, Worcester, MA, United States.

A094 **Myofibroblast programming blocks differentiation of immune enhancingfibroblastic reticular cells in pancreatic cancer**. Andrew Gunderson. The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States.

A095 **Oncogenic KRAS signaling mediates NF-kB induced chemokine production by pancreas tumor cell**. Donovan Drouillard. Medical College of Wisconsin, Milwaukee, WI, United States.

A096 **Re-Phen, a phenformin analogue potentiates anti-PD-1 immunotherapy by enhancing T cell mitochondrial energetics**. Chun Li. The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

A097 **Role of the Receptor for Advanced Glycation Endproducts in the tumor microenvironment for PDAC progression**. Maria Salcedo Noriega. University of Alabama at Birmingham, Birmingham, AL, United States.

A098 **Single nuclear profiling reveals type I IFN-mediated immune remodeling in platinum-refractory HRD-mutant PDAC responsive to checkpoint immunotherapy**. Elena Shersher. University of Miami, Miami, FL, United States.

A099 **Standard chemotherapy in patients with pancreatic ductal adenocarcinoma modulates B cell education within and outside tertiary lymphoid structures**. Charu Arora. University of Pittsburgh, Pittsburgh, PA, United States.

A100 **Systemic targeting of therapeutic RNA into pancreatic tumors via an RNA-binding and cell-penetrating antibody**. Diana Martinez-Saucedo. Yale University, New Haven, CT, United States.

A101 **Targeting ATF4 reshapes PDAC's tumor microenvironment to enhance CAR T-cell anti-tumor efficacy**. Nektarios Kostopoulos. University of Pennsylvania, Philadelphia, PA, United States.

A102 **Targeting serpin B9 to improve pancreatic cancer immunochemotherapy**. Song Li. University of Pittsburgh School of Pharmacy, Pittsburgh, PA, United States.

A103 **Targeting STAT3 in cancer-associated fibroblasts reprograms the stroma and enhances CD8$^+$ T cell-mediated immunity in PDAC**. Ioannis Paraskevaidis. University of Pennsylvania, Philadelphia, PA, United States.

A104 **The CA19-9 glycan is a viable target for CAR T cell therapy in PDAC**. Feiyan Mo. University of Pennsylvania, Philadelphia, PA, United States.

A105 **Therapeutic Reprogramming Of Tumor-Associated Macrophages In Pancreatic Cancer Using A Cytotoxic CCR2-Targeted Nanotheranostic**. Vikas Somani. Washington University School of Medicine, St.Louis, MO, United States.

A106 **Tracing the immune landscape: Temporal and spatial remodeling during pancreatic cancer progression**. Atul Verma. Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.

A107 **A novel theranostic approach targeting ATM-deficient pancreatic ductal adenocarcinoma (PDAC) using177Lu-labeled anti–TRA-1-60**. Nasrin Movahhedin. Wayne state university, Detroit, MI, United States.

A108 **A Tissue-Specific Hydrogel Promotes the Enrichment of Pancreatic Cancer Stem Cells**. Beatriz Magalhães Gomes. University of São Paulo, School of Animal Science and Food Engineering (FZEA), Department of Veterinary Medicine, Pirassununga, Brazil.

A109 **Actin cytoskeleton dynamics in tumor cells mediate Immune-suppressive microenvironment and sensitize pancreas tumors to PD-1 blockade therapy**. Bharti Garg. Moores Cancer Centre UC San Diego, La jolla, CA, United States.

A112 **Breaking BRD4: Tailoring E3 ligase recruitment for tumor-selective MYC suppression in pancreatic cancer**. Steven McKay. Binghamton University, Johnson City, NY, United States.

A113 **Cachexia and Depression in Pancreatic Cancer (PC) Associate with Myeloid Inflammation and Tumor-Intrinsic Metabolic Stress**. Junmin Song. Memorial Sloan Kettering Cancer Center, New York, NY, United States.

A114 **CCK-B Receptor Blockade with Proglumide Enhances Antitumor Activity and Persistence of CD8^{+}CD161^{+} CAR-T Cells in Pancreatic Ductal Adenocarcinoma**. Nalini Bisht. Baylor College of Medicine, Houston, TX, United States.

A115 **Clinical advancement of DUO-207: An ultrasmall nanomedicine delivering a gemcitabine prodrug encapsulating paclitaxel for the treatment of metastatic pancreatic cancer.**. Katherine Eichinger. Duo Oncology, Pittsburgh, PA, United States.

A116 **Combined KRAS and AXL inhibition synergizesin PDAC**. Fredrik Thege. UT MD Anderson Cancer Center, Houston, TX, United States.

A117 **Co-priming sonic hedgehog inhibitor sonidegib with plerixafor induces tumor microenvironment transformation that enhances fluorescent nanoparticle depositionin pancreatic tumor xenograft**. Jonathan Perri. State University of New York at Buffalo, Buffalo, NY, United States.

A118 **Daraxonrasib, a RAS(ON) multi-selective inhibitor, exhibits potent antitumor activity and combinatorial benefit with standard of care chemotherapy and with anti-PD-1 in preclinical models of KRAS G12R PDAC**. Urszula Wasko-Kornberg. Revolution Medicines, Redwood City, CA, United States.

A119 **Designing tumor-targeting nanoparticles for the delivery of therapeutic payloads in pancreatic ductal adenocarcinoma**. Haruka Mori. UMass Chan Medical School, Worcester, MA, United States.

A120 **Disrupting PAR-1-mediated protease signaling in the PDAC tumor and its microenvironment**. Jessica Occhiuto. Indiana University, Indianapolis, IN, United States.

A121 **Dual mechanism nanomedicine targeting drug resistance in pancreatic ductal adenocarcinoma (PDAC)**. Leslie Sloan. OmniNano Pharmaceuticals, Houston, TX, United States.

A122 **Dual targeting of de novo and salvage nucleotide synthesis pathways as a therapeutic strategy in pancreatic cancer**. Shivam Vij. The Ohio State University, Columbus, OH, United States.

A123 **Dual-Drug Micellar Approach to Overcome Stromal Barriers in Pancreatic Cancer**. Fatima Dagher. University of Houston, Houston, TX, United States.

A124 **Early bystander effect of vaccine boosting of CAR T cells reinvigorates endogenous anti-tumor T cell immunity to regress pancreatic cancer**. Leyuan Ma. UPenn/CHOP, Philadelphia, PA, United States.

A125 **Tumor cell plasticity, stromal rewiring, and clonal T cell expansion define response and resistance to combined PARP and PD-1 blockade (POLAR) in pancreatic cancer.**. Marc Hilmi. Memorial Sloan Kettering Cancer Center, New York, NY, United States.

A126 **Tumor-informed ctDNA, ddPCR, CA19-9, and CEA to evaluate early treatment dynamics in patients with metastatic pancreatic cancer**. James Lee. Northwell Health, New Hyde Park, NY, United States.

A127 **Vascular heterogeneity influences treatment responsein pancreatic cancer**. William Sullivan. University of Pennsylvania, Philadelphia, PA, United States.

A128 **Vitamin B3 derivatives support pancreatic cancer cell survival and chemotherapy resistance**. Faith Nakazzi. Case Western Reserve University, Cleveland, OH, United States.

Poster Session B (To be presented on September 30 from 6-9 p.m.)

B001 **Effective targeting p53 mutant pancreatic cancerby novel drug-combination strategy leveraging their DNA damage liabilities**. Andrei Bakin. Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.

B002 **Effects of Proglumide with Chemotherapy on the Pancreatic Tumor Microenvironment: Phase 1 PROGEM Trial**. Jill Smith. Georgetown University, Washignton, DC, United States.

B003 **Therapeutic targeting of the nuclear pore complex with molecular glue degraders in pancreatic cancer**. Steven Corsello. Stanford University, Stanford, CA, United States.

B004 **EMT-associated integrin signaling drives resistance to RAS-GTP inhibition in pancreatic cancer**. Joshua Choe. Dana-Farber Cancer Institute, Boston, MA, United States.

B005 **Exploiting chemotherapy-induced vulnerabilities in pancreatic ductal adenocarcinoma (PDAC) to improve treatment outcomes**. Brooke Pereira. Garvan Institute of Medical Reserch & The Kinghorn Cancer Centre, Sydney, Australia.

B006 **Exploiting Myeloid-Stromal IL1RAP as a Therapeutic Vulnerability to Improve Chemoimmunotherapy Sensitivity in Pancreatic Cancer**. Harper Marsh. University of Miami Miller School of Medicine, Miami, FL, United States.

B008 **Ex-vivo organotypic tumor model of metastatic core biopsy serve as a pragmatic platform for real-time personalized therapy in pancreatic adenocarcinoma**. Naveen Chandrashekhar. Medical College of Wisconsin, Milwaukee, WI, United States.

B009 **Fibulin-3 drives tumor progression and microenvironment remodeling in CA19-9-induced pancreatic ductal adenocarcinoma**. Hyemin Song. Salk Institute for Biological Studies, La Jolla, CA, United States.

B011 **Functional interrogation of the pancreatic intratumoral microbial niche reveals tumor modulation and reshaping of the microenvironment**. Vidhi Chandra. University of Texas MD Anderson Cancer Center, Houston, TX, United States.

B012 **GOT1 inhibition drives remodeling of the extracellular matrix in pancreatic cancer**. Rodrigo Curvello. Monash University, Clayton, Australia.

B013 **Hepatocyte STAT3 signaling drives response to immunotherapy in pancreatic cancer**. John McVey. University of Pennsylvania, Philadelphia, PA, United States.

B014 **Histopathological assessment of irreversible electroporation in ex vivo perfused human pancreatic cancer**. Zainab Rai. University College London, London, United Kingdom.

B016 **Interrupting Hsp70–TLR2 axis to inhibit MerTK activation: A strategy for pancreatic cancer immunotherapy**. Ahmet Kaynak. University of Cincinnati, Cincinnati, OH, United States.

B017 **Moderate hyperthermia as adjuvant therapy for Pancreatic Ductal Adenocarcinoma (PDAC): Pleiotropic effects may modulate drug cytotoxicity**. Robin Colenbier. University of Antwerp, Antwerp, Belgium.

B019 **Neoadjuvant photodynamic therapypotentiatesanti-PD1 therapy in a murine pancreatic cancer model**. Derek Allen. Wellman Center for Photomedicine, Harvard Medical School and Massachusetts General Hospital, Boston, MA, United States.

B020 **Oncogenic KRAS drives nutrient transport to support growth in pancreatic cancer**. Harshita Khedkar. Cornell University, Ithaca, NY, United States.

B022 **Reprogramming Apoptotic Resistance in PDAC Through Synthetic Oncolytic Immunotherapy**. Aleksandra Cios. University of Maryland School of Medicine, Baltimore, MD, United States.

B023 **RepurposingoftheSP/NK1R-complex inhibitor aprepitantin hepatopancreatic malignancies**. Matthias Ilmer. Mayo Clinic, Rochester, MN, United States.

B024 **SHP2-ProTAC Unleashes Potent Antitumor Efficacy against KRAS-Mutant Pancreatic Cancer.**. Xiaobo Li. Beijing Tide Pharmaceutical Co.,LTD, BEIJING, Taiwan (Greater China).

B025 **Star Copolymer-Mediated Delivery of Anti-miRNA Therapeutics for Pancreatic Cancer**. Sofia Miron-Barroso. Imperial College London, London, United Kingdom.

B026 **Sustained KRAS-MAPK Inhibition Induces Interferon-mediated Epithelial-to-Mesenchymal Transition and Reveals a Potential Therapeutic Opportunity**. Ashenfi Bulle. Washington University in School of Medicine in Saint Louis, Saint Louis, MO, United States.

B027 **Synergism of SUMOylation Inhibition with Irinotecan for the Treatment of Pancreatic Cancer**. Asimina Courelli. University of California, San Diego, La Jolla, CA, United States.

B028 **Synthetic lethality (SL) for pancreas cancer (PC) therapy: 'Reading between the lines' of the p53 transcriptional (Tr) readout**. Farah Mazahreh. UAMS, Little Rock, AR, United States.

B029 **TAK1 blockade induces DNA damage and immunogenic cGAS–STING pathway activation in pancreatic cancer**. Sapana Bansod. Washington University School of Medicine, St. Louis, MO, United States.

B030 **Targeting DDR2 for Treating Pancreatic Cancer**. Chris Do. UT Health San Antonio, San Antonio, TX, United States.

B031 **Targeting hyaluronic acid in pancreatic ductal adenocarcinoma uncovers novel therapeutic opportunities**. Pian Sun. Centro Nacional de Investigaciones Oncológicas, Madrid, Spain.

B032 **Targeting Lipid Rafts in Hypoxic Pancreatic Ductal Adenocarcinoma: Preclinical Evaluation of [225Ac]CLR 121225, a Novel Actinium-Based Radio-Conjugate**. Jarrod Longcor. Cellectar Biosciences Inc, Florham Park, NJ, United States.

B033 **Targeting NELFE using antisense oligonucelotides reduces tumor burden and increases overall survival in vivo**. Brittany Ruiz. Thomas Jefferson University, Philadelphia, PA, United States.

B034 **Efficacy of Tumor Treating Fields (TTFields) together with gemcitabine and nab-paclitaxel (Gem/NabP) for treatment of pancreatic cancer, in vitro and in vivo**. Tal Kan. Novocure Ltd, Haifa, Israel.

B035 **Tumor Treating Fields (TTFields) together with FOLFIRINOX are effective for the treatment of pancreatic cancer, in vitro and in vivo**. Tal Kan. Novocure Ltd, Haifa, Israel.

B036 **Uncovering the dual roles of XBP1 in pancreatic ductal adenocarcinoma during lipid imbalance and KRAS inhibitor resistance**. Yanqing (Christine) Jiang. University of Pennsylvania, Philadelphia, PA, United States.

B037 **Validation and translation of therapeutic potential of thrombin-PAR1 signaling in suppressing fibrosis using microphysiological PDAC tumor models**. Bumsoo Han. University of Illinois Urbana-Champaign, Urbana, IL, United States.

B038 **Vertical RAS-pathway inhibition in pancreatic cancer drives therapeutically exploitable mitochondrial alterations**. Philipp Hafner. Medical Center – University of Freiburg, Freiburg im Breisgau/ Germany, Germany.

B039 **Wild-Type IDH1 inhibition enhances PARP inhibitor sensitivity in pancreatic cancer**. Mehrdad Zarei. Case Western Reserve University, CLEVELAND, OH, United States.

B040 . Aaliyah Balagtas. Sanford Burnham Prebys NCI-designated Cancer Center, San Diego, CA, United States.

B041 **Spontaneous Tumor Lysis Syndrome Associated with Pancreatic Adenocarcinoma: A Case Report**. Manas Pustake. Texas Tech University Health Sciences Center El Paso, El Paso, TX, United States.

B042 **A micro-vascularized organ-on-chip model of PDAC reveals immune exclusion and altered macrophage polarization**. Thomas Sommermann. Dynamic42 GmbH, Jena, Germany.

B043 **Actionable Mutational Landscape of Pancreatic Cancer in Puerto Rican Hispanics: Implications for Targeted Therapy**. Veroushka Ballester. University of Puerto Rico Comprehensive Cancer Center, San Juan, Puerto Rico.

B044 **Black and Hispanic patients with pancreatic ductal adenocarcinoma (PDAC) have worse overall survival than Asian and White patients with PDAC, despite having more favorable genetic profiles.**. Jhoely Duque-Jimenez. Weill Cornell Medicine, New York, NY, United States.

B045 **Bridging Psychosocial Support and Clinical Navigation in Pancreatic Cancer: A Foundation-Led Model for Patient Advocacy**. Steven Merlin. SeenaMagowitzFoundation.org, Alexandria, VA, United States.

B046 **Discovery of a fibroblast subtype enriched in long-term survivors of PDAC**. Alex Blain. Dana-Farber Cancer Institute, Boston, MA, United States.

B047 **DNA Damage Repair (DDR) Variants Beyond BRCA/PALB2 in Pancreatic Adenocarcinoma (PDAC): Evaluation of Significance**. Catherine O'Connor. Harvard Medical School, Boston, MA, United States.

B048 **Loss of Bmi1 disrupts regeneration of the pancreas after injury.**. Joyce Thompson. Universisty of Michigan, Ann Arbor, MI, United States.

B049 **Pancreatic cancer cachexia is mediated by PTHrP-driven disruption of adipose de novo lipogenesis**. Nikita Bhalerao. UMass Chan Medical School, Worcester, MA, United States.

B050 **Patient-matched EUS-FNB-derived organoid-CAF co-culture platform reveals novel resistance mechanisms in pancreatic cancer**. Kyung Min Lee. Seoul National University Hospital, Seoul, Korea, Republic of.

B051 **Trends in pancreatic cancer and renal failure-related mortality among adults in the United States from 1999 to 2020.**. Sravani Bhavanam. Brookdale Univeristy hospital and medical center, Brooklyn, NY, United States.

B052 **Trends in Thromboembolism-Related Mortality Among Patients with Pancreatic Cancer in the United States: A CDC WONDER Analysis (1999–2023)**. Sravani Bhavanam. Brookdale University hospital and medical center, Brooklyn, NY, United States.

B054 **A methylation specific PCR multi-cancer early detection (MCED) test detects pancreatic cancer**. Richard Bernert. Precision Epigenomics Inc, TUCSON, AZ, United States.

B055 **A Multimodal Machine Learning Approach for Early Detection of Pancreatic Cancer**. Chun-Mei Hu. Genomics Research Center, Academia Sinica, Taipei, Taiwan, Taipei, Taiwan (Greater China).

B056 **Advancing early detection of pancreatic cancer with BlueSCAI, a novel high-sensitivity, multiplexed biomarker technology.**. Malcolm MacKenzie. ActivSignal LLC, Natick, MA, United States.

B057 **Antibody-based drug targeting of the KRAS inhibitor-induced pancreatic cancer cell surfaceome**. Fan Yi Kong. Dana-Farber Cancer Institute, Boston, MA, United States.

B058 **Beyond case reports: Defining prognosis, biomarkers, and genomic patterns in pancreatic acinar cell carcinoma**. Rebecca Germaine. Department of Biostatistics, George Washington Milken School of Public Health, Washington, DC, United States.

B059 **Blood proteomic profiles and pancreatic ductal adenocarcinoma risk – A Mendelian randomization and observational analysis**. Ting Zhang. National Cancer Institute, Rockville, MD, United States.

B060 **ERMCS inductiondrives ADM inex vivomodels**. Mariana Tannús Ruckert. University of Michigan, Ann Arbor, MI, United States.

B061 **Evaluating the Burden of Untreated Pancreatic Cancer**. Adrianna Kapusta. Northwell Health Cancer Institute, Lake Success, NY, United States.

B062 **Extracellular vesicle based ALPPL2 and THBS2 as biomarkers for disease monitoring in pancreatic cancer patients undergoing neoadjuvant therapy**. KUNTAL HALDER. The Translational Genomics Research Institute, Phoenix, AZ, United States.

B063 **Immune cell expression-based multi-biomarker blood panel for early detection of pancreatic ductal adenocarcinoma**. SO YOUNG KIM. yonsei university, Seoul, Korea, Republic of.

B064 **Impact of germline pathogenic variants on pancreatic cancer screening and outcomes**. Pranati Shah. Loma Linda University, irvine, CA, United States.

B066 **New DiagnosticBiomarkers for Malignant/Mucinous Pancreatic Cysts using Lipidomics**. Hongsun Kim. University of Michigan, Ann Arbor, MI, United States.

B067 **Novel Biological and Radiological Markers for Predicting Malignant Progression in IPMN: A Prospective Study**. Benedetta Ferrara. Diabetes Research Institute, San Raffaele Scientific Institute, Milan, MI, Italy.

B068 **Novel Liquid Biopsy Gene Panel for Potential Early Diagnosis of PDAC with High Accuracy**. Srinivas Koduru. Wren Laboratories LLC, Branford, CT, United States.

B069 **On the development of the Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts biobank**. Janet Olson. Mayo Clinic, Rochester, MN, United States.

B070 **Pancreatic Cancer Detection Consortium biomarker bake-off: A consortium Phase 2 blinded biomarker validation and panel discovery study**. Ann Oberg. Mayo Clinic, Rochester, MN, United States.

B071 **Physiologic Duodenal Aspiration Liquid Biopsy Enables Early Risk Stratification in Pancreatic Cystic Neoplasms**. Aleksei Kashintsev. Pandica LTD, London, United Kingdom.

B072 **Plasma whole-genome sequencing to monitor pancreatic cancer**. Yuanchang Fang. The University of Toronto, Toronto, Canada.

B073 **Predicting pancreatic cancer risk from clinical notes using large language models**. Daniel Mau. University Health Network; ICES; University of Toronto, Toronto, ON, Canada.

B074 **scRNA-seq from FFPE tissue resolves the tumor microenvironment of intraductal papillary mucinous neoplasms**. Ashley Fletcher. Duke University Medical Center, Durham, NC, United States.

B075 **Young- and older-onset pancreatic cancers arise through distinct mechanisms: Insights from genomic and germline analyses**. Chen Yuan. Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, United States.

B076 **Clinical and Molecular Characteristics of KRASQ61Mutated Pancreatic Cancer and Other Gastrointestinal Malignancies**. Dan Zhao. The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

B077 **Pre-clinical evaluation of a potent and plasma-stable Pin1 degrader in a mouse model of pancreatic cancer**. Tiane Li. City of hope, Duarte, CA, United States.

B078 **The novel small molecule inhibitor LLS132 reduces pancreatic cancer growth, in part, through modulation of the cell cycle pathway**. Irena Krga. University of California Davis, Davis, CA, United States.

B079 **An increase in neural cancer associated fibroblasts following exposure to chemotherapy in pancreatic ductal adenocarcinoma**. Aylin Henstridge. University of Michigan, Ann Arbor, MI, United States.

B080 **Assessing the response of 3D human pancreatic tumor explants to standard chemotherapy**. George Sharbeen. UNSW Sydney, Sydney, Australia.

B081 **Association between clonal hematopoiesis and survival outcomes in pancreatic ductal adenocarcinoma: Analysis from the PASS-01 trial**. Panot Sainamthip. Dana-Farber Cancer Institute, Boston, MA, United States.

B082 **Clonal dynamics and molecular mechanisms mediating resistance to RAS inhibition**. Jayne McDevitt. University of Pennsylvania, Philadelphia, PA, United States.

B083 **Defining a molecular basis and therapeutic approach for KEAP1-NRF2 mediated resistance to KRAS inhibition in KRAS-mutant pancreatic ductal adenocarcinoma**. Wen-Hsuan Chang. University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.

B084 **Development of 3D organoid models from patient-derived conditionally reprogrammed cells in pancreatic cancer**. Galam Leem. Division of Gastroenterology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea, Seoul, Korea, Republic of.

B086 **External validation of a multimodal machine learning system to predict outcomes in advanced pancreatic cancer in the PASS-01 trial**. Wei Quan. University Health Network, Toronto, ON, Canada.

B087 **Feasibility study of an ex vivo functional precision medicine platform, Optim.AI™, in guiding treatment for pancreatic cancer**. Edward Chow. KYAN Technologies Pte Ltd, Singapore, Singapore.

B089 **Identification of splicing factor U1A as a key regulator of aggressive subtypes in pancreatic cancer**. Mari Nakamura. Columbia University, New York, NY, United States.

B090 **Integrated radiomic-molecular model enhances early prediction of progression in advanced pancreatic cancer patients treated with gemcitabine/nab-paclitaxel with or without tocilizumab**. Kevin Zi Ming Lim. Herlev Hospital, University of Copenhagen, Denmark, Herlev, Denmark.

B091 **Interleukin-1 Receptor Accessory Protein (IL1RAP) overexpression is associated with worse outcome in PDAC and can be reversed by nadunolimab treatment**. Camilla Rydberg Millrud. Cantargia AB, LUND, Sweden.

B092 **Investigating combination therapies to overcome RAS inhibitor resistance in pancreatic cancer**. Vasiliki Pantazopoulou. Salk Institute for Biological Studies, La Jolla, CA, United States.

B093 **Investigating mechanisms of PARP inhibitor resistance in homologous recombination deficient PDAC using patient-derived organoid models**. Austin Good. University of Pennsylvania, Philadelphia, PA, United States.

B094 **Ketogenic Diet Modulates Gut Microbiome Composition and Enhances Treatment Response in Patients with Advanced Pancreatic Cancer: A Phase II Study**. Keehoon Lee. Translational Genomics Research Institute (TGen), TGen Integrated Microbiomics Center, Flagstaff, AZ, United States.

B095 **Minimally invasive fluid-derived organoids enable modeling of chemotherapy resistance in pancreatic ductal adenocarcinoma**. Hee Seung Lee. Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of.

B096 **Mutant and Wildtype RAS Crosstalk and Stoichiometric Deficiencies Determine Sensitivity to RAS Pathway Targeted Therapies**. Thomas McFall. Medical College of WI, Wauwatosa, WI, United States.

B097 **pan-RAS-GTP inhibition relieves angiosuppression in PDAC by repressing Hedgehog paracrine signaling**. Kenneth Olive. Columbia University Irving Medical Center, New York, NY, United States.

B098 **RAS(ON) multi-selective inhibition remodels cancer-associated fibroblast subtypes and extracellular matrix in pancreatic cancer**. Marie Hasselluhn. Department of Medicine, Division of Digestive and Liver Diseases, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center; Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, United States.

B099 **Spatial identification of favorable molecular modulations after stereotactic body radiotherapy in pancreatic cancer with a practical staining-based classifier**. Christelle Bouchart. Institut Jules Bordet - H.U.B., Brussels, Belgium.

B100 **Spatial relationships between tumor subtypes and tumor-promoting CAFs with clinical implications**. Xianlu Peng. The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.

B101 **TNFR-MK2 Signaling Drives Autophagy and Resistance to KRAS/MAPK Inhibition in Pancreatic Cancer**. Ofejiro Pereye. Washington University in St. Louis, St. Louis, MO, United States.

B102 **A model for the origins of transcriptional heterogeneity in human pancreatic ductal adenocarcinoma**. Sabrina Ge. Princess Margaret Cancer Centre, Toronto, ON, Canada.

B103 **Defining cancer cell states that drive inflammation tolerance and KRAS inhibitor resistance in pancreatic cancer**. Yuzhou Tong. MIT, Cambridge, MA, United States.

B104 **Dissecting myeloid - cancer communication networks in pancreatic cancer**. Cavina Lee. UC Irvine, Irvine, CA, United States.

B105 **Distinct cancer-associated fibroblast populations induced by epithelial and mesenchymal PDAC subtypes in a xenograft model**. Kyu Min Lim. Severance Hospital Yonsei University College of Medicine, Seoul, Korea, Republic of.

B106 **Elucidating the clonal dynamics andepigenetic regulators of PDAC initiation in inducible neoplastic organoid models**. Connor Hennessey. University of Pennsylvania, PHILADELPHIA, PA, United States.

B107 **FOXA1/2 and HNF4α Regulate Molecular Subtype and Therapeutic Response in Pancreatic Ductal Adenocarcinoma**. Walter Orellana. University of Utah, Salt Lake City, UT, United States.

B108 **Functional Dissection of the Highly Plastic Basal Cell State in Pancreatic Cancer**. Anupriya Singhal. Memorial Sloan Kettering Cancer Center, New York, NY, United States.

B109 **Heterogeneity of S100A2, KRT17, and KRT5 in donor Pancreatic Intra-epithelial neoplasia and donor-derived Organoids**. Jude Okoye. University of Michigan, ANN ARBOR, MI, United States.

B110 **High-dimensional spatial analysis of murine PDAC microenvironment emphasizes primary and metastatic immune heterogeneity**. Christina Larson. University of Alabama at Birmingham, Birmingham, AL, United States.

B111 **HMGA2 and protein leucine methylation drive pancreatic cancer lineage plasticity**. Sita Kugel. Fred Hutchinson Cancer Center, Seattle, WA, United States.

B112 **HMGA2 Predicts Treatment Outcome in Pancreatic Cancer**. Naomi Yamamoto. University of Washington, Seattle, WA, United States.

B113 **Imaging mass cytometry guided shallow whole genome sequencing for phenotype informed regional copy number profiling in a pancreatic tumor**. Tiak Ju Tan. Lunenfeld Tananbaum Research Institute, Toronto, Canada.

B115 **Integrated spatial and multi-omic analysis reveals functional niches in the pancreatic cancer microenvironment**. Noor Shakfa. Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada.

B116 **Integrative proteogeonomic profiling of PDAC reveals updated epithelial subtypes and cross-omic predictors of survival**. Ferris Nowlan. University of Toronto, Toronto, ON, Canada.

B117 **Intraductal Papillary Mucinous Neoplasm Cellular Plasticity Linked with Repeat Element Dysregulation**. Amaya Pankaj. Krantz Family Center for Cancer Research, Boston, MA, United States.

B118 **Investigating the tumor microenvironment's role in lineage fate determination in pancreatic ductal adenocarcinoma**. Jennifer Claire Muscat. Cancer Research UK Scotland Institute, Glasgow, United Kingdom.

B119 **LY6D identifies persistent tumor-initiating cells driving pancreatic tumorigenesis**. Jing Xue. Shanghai Jiaotong University School of Medicine, Shanghai, Taiwan (Greater China).

B120 **Mapping and modulating epithelial-mesenchymal plasticity under RAS(ON) multi-selective inhibition in PDAC through lineage tracing and Perturb-seq.**. Julien Dilly. Dana-Farber Cancer Institute, Boston, MA, United States.

B121 **Morphospatial profiling of cancer-associated fibroblasts reveals architectural subtypes of pancreatic ductal adenocarcinoma**. Adam Bryce. University of Glasgow, Glasgow, United Kingdom.

B122 **Multimodal Validation of a Plastic Transitional State in Pancreatic Ductal Adenocarcinoma**. Lyanne Delgado Coka. Stony Brook University, Stony Brook, NY, United States.

B123 **Phenotypic, Microenvironmental, and Genetic Crosstalk Shapes Pancreatic Cancer Organization**. Ofer Elhanani. Weizmann Institute of Science, Rehovot, Israel.

B124 **Rapid, high-plex spatial proteomic profiling of pancreatic cancer using a pancreas-focused-assay and customized analysis workflow**. Andressa Dias Costa. Dana Farber Cancer Institute, Boston, MA, United States.

B125 **Resolving PDAC cell subpopulations that seed metastatic recurrence**. Ali Moursy. Van Andel Institute, Grand Rapids, MI, United States.

B126 **Single-cell and spatially resolved atlas of pancreatic cancer reveals immunophenotypes associated with clinical outcome**. Gabriel Francisco Pozo de Mattos Pereira. UFCSPA, Porto Alegre, Brazil.

B127 **Spatial profiling reveals cancer cell metabolic cooperation with aggregative neutrophils in pancreatic cancer**. Carson Poltorack. University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, United States.

B128 **Spatial proteomics extend tumour subtype and microenvironment classifications across genotype-phenotype axes of pancreatic cancer.**. Hartland Jackson. Lunenfeld Tanenbaum Research Institute, Toronto, ON, Canada.

B129 **Tracking genome evolution and chemoresistance in pancreatic cancer**. Audrey Lumeau. Barts Cancer Insitute, Queen Mary University of London, London, United Kingdom.